Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study
Richardson, Paul G, Jagannath, Sundar, Moreau, Philippe, Jakubowiak, Andrzej J, Raab, Marc S, Facon, Thierry, Vij, Ravi, White, Darrell, Reece, Donna E, Benboubker, Lotfi, Zonder, Jeffrey, Tsao, L Claire, Anderson, Kenneth C, Bleickardt, Eric, Singhal, Anil K, Lonial, Sagar
Published in The Lancet. Haematology (01.12.2015)
Published in The Lancet. Haematology (01.12.2015)
Get more information
Journal Article